Cancer Diagnostics Market: Growth Trends, Drivers, and Future Outlook
The global cancer diagnostics market is undergoing a significant transformation as the worldwide burden of cancer continues to climb and healthcare systems race to detect the disease earlier and more accurately. The market was valued at USD 17.24 billion in 2025 and is projected to grow from USD 18.51 billion in 2026 to USD 38.27 billion by 2034, registering a CAGR of 9.5% during the forecast period, according to Fortune Business Insight. This steady expansion reflects a broader shift in oncology care, where early and precise diagnosis is increasingly viewed as the foundation of effective treatment rather than a secondary step in the care pathway.
Rising Cancer Burden Fuels Demand
At the heart of this market’s growth is the sheer scale of the global cancer burden. New cancer cases worldwide are expected to reach 35 million by 2050, an increase of 77% from 20 million cases in 2022, according to Fortune Business Insight. This escalating disease burden has pushed healthcare providers, governments, and diagnostic companies to prioritize technologies that can identify cancer at its earliest, most treatable stages. Techniques such as immunohistochemistry, in-situ hybridization, immunoassays, and molecular diagnostics are central to this effort, helping clinicians distinguish between cancer types and subtypes with far greater precision than was possible a decade ago.
Government and public health bodies have also stepped up awareness and screening initiatives. Programs such as the World Health Assembly’s Global Strategy for Cervical Cancer Elimination and various national colorectal screening initiatives have reinforced the message that early detection saves lives, further strengthening demand for diagnostic tools, according to Fortune Business Insight.
Innovation and R&D Driving Market Expansion
Diagnostic companies are investing heavily in research and development to bring more advanced, accurate, and efficient products to market. Expanded partnerships, such as those focused on companion diagnostics covering next-generation sequencing (NGS), digital pathology, polymerase chain reaction (PCR), and immunoassay technologies, have been a key growth lever, according to Fortune Business Insight. Artificial intelligence is also emerging as a transformative force, being deployed for risk profiling, image analysis, and reducing false positives in screenings such as lung cancer detection.
Liquid biopsy is another area of rapid innovation. Though tissue biopsy continues to dominate due to its diagnostic accuracy, liquid biopsy is gaining traction for its speed — delivering NGS results roughly 26.8 days faster than tissue biopsy, according to Fortune Business Insight. This speed advantage is particularly valuable for cancers like lung and breast cancer, where timely treatment decisions matter.
Market Segmentation Insights
By product, assay kits & reagents will account for 83.07% of the market in 2026, driven by the sheer volume of diagnostic testing conducted globally, according to Fortune Business Insight. Instruments, while smaller in share, are expected to grow steadily as healthcare spending rises across regions.
By type, tissue biopsy is projected to hold 87.04% of the market in 2026 owing to its accuracy and depth of molecular information, while liquid biopsy is expected to post the fastest growth rate over the forecast period, according to Fortune Business Insight.
By end-user, clinical laboratories led the market, supported by the scale of testing infrastructure — with roughly 4 billion diagnostic tests conducted annually in the U.S. alone, according to Fortune Business Insight. Hospitals and clinics are expected to grow at a notable pace as well, driven by patient preference for combined diagnosis and treatment at a single facility.
Regional Landscape
North America remains the dominant regional market, contributing 36.81% of global revenue in 2025 with a valuation of USD 6.35 billion, projected to reach USD 6.9 billion in 2026, according to Fortune Business Insight. This leadership position is underpinned by the strong presence of major players such as Thermo Fisher Scientific, Abbott, Illumina, and GE Healthcare.
Europe followed with USD 5.28 billion in 2025, representing 30.65% of the global market, and is projected to reach USD 5.63 billion in 2026, according to Fortune Business Insight. The region’s growth is being driven by precision oncology initiatives, including large-scale genomic profiling programs aimed at advancing personalized cancer care.
Asia Pacific, valued at USD 3.78 billion in 2025 and capturing 21.95% of global revenue, is projected to reach USD 4.07 billion in 2026, according to Fortune Business Insight. The region is expected to grow at a significant pace as healthcare infrastructure investment increases and diagnostic accessibility improves across emerging economies.
Restraints and Opportunities
Despite strong growth, the market faces challenges. High costs associated with diagnostic equipment — PCR machines alone can range from USD 3,000 to USD 30,000 — along with procedural risks tied to tools like colonoscopy, continue to limit adoption in cost-sensitive and emerging markets, according to Fortune Business Insight.
At the same time, opportunities are emerging from the expansion of diagnostic capabilities in underserved regions and the growing role of telemedicine in cancer follow-up and consultation. These trends, combined with ongoing advances in biomarker-based diagnostics and personalized medicine, are expected to shape the competitive landscape well into the next decade.
Competitive Landscape
The market remains led by established players such as F. Hoffmann-La Roche, Thermo Fisher Scientific, and Abbott, alongside Illumina, GE Healthcare, BD, bioMérieux, Myriad Genetics, Bio-Rad Laboratories, and QIAGEN, according to Fortune Business Insight. These companies continue to pursue new product launches, FDA approvals, and strategic partnerships — including AI-powered diagnostic collaborations — to strengthen their market positions.
Conclusion
The cancer diagnostics market is set for sustained, robust growth through 2034, propelled by the rising global cancer burden, continuous technological innovation, and expanding access to advanced screening tools across both developed and emerging markets. As diagnostic accuracy and speed continue to improve, the industry is poised to play an increasingly central role in reducing cancer mortality worldwide.
What’s Driving Japan’s Market? Discover the Latest “Cancer Diagnostics Market” Insights